Dr Teng Leyan, PhD, Joins K2 Capital's Advisory Board

Febuary 14th, 2025 – We are excited to announce the addition of Teng Leyan, PhD, as a strategic advisor. Dr. Teng is the founder of R&G (Stock Code: 301333 SZ), a leading clinical research organization with a global footprint. Her background includes a Doctorate in Clinical Pharmacology from the NUS and an EMBA from Tsinghua University. She has also spent more than a decade at Lilly Clinical Pharmacology Center, refining clinical trial methodologies to improve patient outcomes and streamline pharmaceutical innovation.

Under her leadership, R&G has grown into a powerhouse of nearly 2,000 professionals, providing comprehensive CRO services that support pharmaceutical enterprises in enhancing drug development success rates, mitigating risks, reducing costs, and accelerating clinical research timelines.

Dr. Teng’s extensive business acumen and leadership experience will be instrumental in shaping K2 Capital’s broader strategic initiatives. Her ability to navigate complex regulatory landscapes, manage large-scale operations, and drive innovation will help K2 Capital expand its influence across multiple industries. Her insights will provide valuable guidance as we continue to invest in, develop and scale AI-driven solutions that address business challenges.